The Otsuka and Noven successes from 2018 portend a new era of drug development, one in which treatment efficacy is established in the context of the patient's overall life and behavior. It is time for measurement science to follow and embrace the fact that how we measure outcomes will evolve from applying one solution to finding an empirical basis for a highly customized application of all of them, enabled by technology. Personalized medicine needs a more personalized approach to measurement.
Request a Genetics in Clinical Trials training session
What You'll LearnMost Recent Flipbooks

Q&A with CNS Expert, Dr. Philip Scheltens
Philip Scheltens, MD, PhD, a member of WCG’s Scientific Leadership Team, shared his insights during a recent conversation with Christopher Randolph, PhD, ABPP-CN, chief scientific officer...

SNAPSI: Bridging the Gap Between Research and Clinical Care in Mental Health
In the field of mental health, there is a discrepancy between how research is conducted and how care is delivered. MedAvante-ProPhase, a WCG company, is collaborating with leaders in health care to...

Q&A with Dr. Sofija Jovic
Increasingly, sponsors are turning to experts who have “been there, done that” to help them develop protocols for their CNS trials. In this wide-ranging interview, Sofija Jovic, PhD, MBA, of WCG...

Q&A with CNS Expert, Dr. Leo Verhagen Metman
Leo Verhagen Metman, a member of WCG’s Scientific Leadership Team, shared his insights during a recent conversation...

Bridging the Measurement Gap Between Research and Clinical Care in Schizophrenia
The aim of this paper is to discuss how the measurement gap between research and clinical care in schizophrenia can be closed.

A Developmental History of the Positive and Negative Syndrome Scale (PANSS)
In this review article, the authors explore the history of the most influential schizophrenia research tools that have been created over the past several decades.

Q&A with CNS Expert, Dr. Scott J. Hunter
Scott J. Hunter, PhD, a member of WCG’s Scientific Leadership Team, shared his insights during a recent conversation with...

Q&A with CNS Expert, Dr. Michael Liebowitz
Dr. Michael Liebowitz, a member of WCG’s Scientific Leadership Team, shared his insights during a recent conversation with...

Q&A with CNS Expert, Dr. Leslie Citrome
Leslie Citrome, MD, MPH, a member of WCG’s Scientific Leadership Team, shared his insights during a recent conversation with Mark Opler, MD, PhD, chief research officer at WCG-MedAvante-ProPhase.

Q&A with CNS Expert, Dr. Christoph U. Correll
Christoph U. Correll, MD, a member of WCG’s Scientific Leadership Team, shared his thoughts in a recent conversation with Mark Opler, MD, PhD, chief research officer at WCG-MedAvante-ProPhase.

CNS Drugs Take Longer to Develop, Win Approval